Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Change in Acquisitions & Divestments (2016 - 2025)

Cytokinetics (CYTK) has disclosed Change in Acquisitions & Divestments for 16 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments changed N/A to $6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $106.4 million, a N/A change, with the full-year FY2025 number at $6.0 million, changed N/A from a year prior.
  • Change in Acquisitions & Divestments was $6.0 million for Q4 2025 at Cytokinetics, down from $275.7 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $721.1 million in Q3 2023 to a low of -$447.0 million in Q4 2022.
  • A 5-year average of $105.0 million and a median of $133.3 million in 2021 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: plummeted 206.54% in 2022, then skyrocketed 3422.12% in 2024.
  • Cytokinetics' Change in Acquisitions & Divestments stood at $419.5 million in 2021, then tumbled by 206.54% to -$447.0 million in 2022, then soared by 132.39% to $144.8 million in 2023, then tumbled by 221.07% to -$175.3 million in 2024, then surged by 103.42% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Change in Acquisitions & Divestments are $6.0 million (Q4 2025), $275.7 million (Q1 2025), and -$175.3 million (Q2 2024).